First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma’s CEO James Sapirstein to Present at Inaugural Roth Healthcare Opportunities Conference
September 28, 2022 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 28, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
September 19, 2022 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 19, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma CEO James Sapirstein to Moderate Panel Discussion at Longwood Healthcare Leaders Fall Webconference
September 14, 2022 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Sept. 14, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ: FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation
September 07, 2022 07:00 ET | First Wave BioPharma, Inc.
Data suggest technology provides improved delayed-release profile that ensures adrulipase is delivered to targeted areas of the GI tract First Wave BioPharma expects to initiate Phase 2 trial...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma Announces AAPS 2022 PharmSci 360 Accepts Adrulipase Formulation Abstract
August 31, 2022 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 31, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma to Present at H.C. Wainwright 24th Annual Global Investment Conference 2022
August 29, 2022 07:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 29, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma, Inc. Announces Reverse Stock Split
August 25, 2022 12:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., Aug. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
22157.jpg
Global Cystic Fibrosis Market Report 2022-2030 - Expanding Therapeutic Options is Expected to Drive Market Growth
August 03, 2022 08:03 ET | Research and Markets
Dublin, Aug. 03, 2022 (GLOBE NEWSWIRE) -- The "Cystic Fibrosis Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts,...
First-Wave-Logo-FINAL-RGB[1].jpg
First Wave BioPharma, Inc. Announces Private Placement
July 15, 2022 08:00 ET | First Wave BioPharma, Inc.
BOCA RATON, Fla., July 15, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
Aceragen Pic.png
Aceragen announces dosing of first patient with ACG-701 in clinical trial for treatment of melioidosis
June 15, 2022 07:30 ET | Aceragen
RALEIGH-DURHAM, NC , June 15, 2022 (GLOBE NEWSWIRE) -- Aceragen, Inc., a clinical-stage biopharmaceutical company developing therapies for rare pulmonary and rheumatic diseases with high unmet...